Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:associated_with |
ovary
kidney endometrium |
| gptkbp:clinical_trial |
Phase IV
Phase II Phase III Phase I |
| gptkbp:genetic_diversity |
gptkb:VHL_gene
PBR M1 gene SET D2 gene |
| gptkbp:grades |
high grade
low grade |
| https://www.w3.org/2000/01/rdf-schema#label |
Clear cell carcinoma
|
| gptkbp:is_characterized_by |
clear cells
|
| gptkbp:is_tested_for |
CA-125
H E4 NM P22 |
| gptkbp:number_of_stages |
stage I
stage IV stage II stage III |
| gptkbp:provides_information_on |
ASCO guidelines
NCCN guidelines ECOG performance status |
| gptkbp:risk_factor |
obesity
family history smoking |
| gptkbp:social_responsibility |
gptkb:healthcare_organization
rare variable imaging studies biopsy more common in adults more common in women clear cell adenocarcinoma cytoplasmic features histological subtype nuclear features serous carcinoma |
| gptkbp:symptoms |
weight loss
abdominal pain hematuria |
| gptkbp:treatment |
gptkb:hospital
gptkb:vaccine clinical trials radiation therapy chemotherapy targeted therapy recurrence remission complete response partial response stable disease |
| gptkbp:bfsParent |
gptkb:Epithelial_ovarian_cancer
|
| gptkbp:bfsLayer |
5
|